Vincent Doré
Vincent Doré
CSIRO eHealth - Biomedical Informatics Group – Medical Image Analysis Team
Verified email at
Cited by
Cited by
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
A Nakamura, N Kaneko, VL Villemagne, T Kato, J Doecke, V Doré, ...
Nature 554 (7691), 249-254, 2018
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
VL Villemagne, V Doré, SC Burnham, CL Masters, CC Rowe
Nature Reviews Neurology 14 (4), 225-236, 2018
Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a …
SC Burnham, P Bourgeat, V Doré, G Savage, B Brown, S Laws, P Maruff, ...
The Lancet Neurology 15 (10), 1044-1053, 2016
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
VL Villemagne, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, J Hodges, ...
European journal of nuclear medicine and molecular imaging 41, 816-826, 2014
Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease
V Doré, VL Villemagne, P Bourgeat, J Fripp, O Acosta, G Chetélat, L Zhou, ...
JAMA neurology 70 (7), 903-911, 2013
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts
RF Buckley, EC Mormino, RE Amariglio, MJ Properzi, JS Rabin, YY Lim, ...
Alzheimer's & Dementia 14 (9), 1193-1203, 2018
Multisite study of the relationships between antemortem [11C] PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
R La Joie, N Ayakta, WW Seeley, E Borys, AL Boxer, C DeCarli, V Doré, ...
Alzheimer's & Dementia 15 (2), 205-216, 2019
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
R Ossenkoppele, A Pichet Binette, C Groot, R Smith, O Strandberg, ...
Nature medicine 28 (11), 2381-2387, 2022
Aβ-amyloid and tau imaging in dementia
VL Villemagne, V Dore, P Bourgeat, SC Burnham, S Laws, O Salvado, ...
Seminars in nuclear medicine 47 (1), 75-88, 2017
Comparison of MR-less PiB SUVR quantification methods
P Bourgeat, VL Villemagne, V Dore, B Brown, SL Macaulay, R Martins, ...
Neurobiology of aging 36, S159-S166, 2015
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
P Chatterjee, S Pedrini, NJ Ashton, M Tegg, K Goozee, AK Singh, ...
Alzheimer's & Dementia 18 (6), 1141-1154, 2022
Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
P Bourgeat, V Doré, J Fripp, D Ames, CL Masters, O Salvado, ...
Neuroimage 183, 387-393, 2018
18F-Florbetaben PET beta-amyloid binding expressed in Centiloids
CC Rowe, V Doré, G Jones, D Baxendale, RS Mulligan, S Bullich, ...
European journal of nuclear medicine and molecular imaging 44, 2053-2059, 2017
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
S Amadoru, V Doré, CA McLean, F Hinton, CE Shepherd, GM Halliday, ...
Alzheimer's research & therapy 12 (1), 22, 2020
Standardized expression of 18F-NAV4694 and 11C-PiB β-amyloid PET results with the Centiloid scale
CC Rowe, G Jones, V Doré, S Pejoska, L Margison, RS Mulligan, ...
Journal of Nuclear Medicine 57 (8), 1233-1237, 2016
Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults
SM Laws, S Gaskin, A Woodfield, V Srikanth, D Bruce, PE Fraser, T Porter, ...
Scientific reports 7 (1), 9766, 2017
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross‐sectional and longitudinal study in the AIBL cohort
P Chatterjee, S Pedrini, JD Doecke, R Thota, VL Villemagne, V Doré, ...
Alzheimer's & Dementia 19 (4), 1117-1134, 2023
Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality …
C Fowler, SR Rainey-Smith, S Bird, J Bomke, P Bourgeat, BM Brown, ...
Journal of Alzheimer's disease reports 5 (1), 443-468, 2021
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease
G Chételat, R Ossenkoppele, VL Villemagne, A Perrotin, B Landeau, ...
Brain 139 (9), 2528-2539, 2016
Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
MR Battle, LC Pillay, VJ Lowe, D Knopman, B Kemp, CC Rowe, V Doré, ...
EJNMMI research 8, 1-11, 2018
The system can't perform the operation now. Try again later.
Articles 1–20